 REHOVOT, Israel, Aug. 05, 2020 GLOBE NEWSWIRE -- Kamada Ltd. NASDAQ TASE: KMDA, plasma-derived biopharmaceutical company, today announced that it will release financial results for the second quarter ended June 30, 2020, prior to the open of the U.S. financial markets on Wednesday, August 12, 2020. Kamada management will host an investment community conference call on Wednesday, August 12, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 855-327-6837 from within the U.S., 1-809-458-327 from Israel, or 631-891-4304 International and entering the conference identification number: 10010379. The call will also be webcast live on the Internet on the Companys website at call will also be archived for 90 days on the Companys website at Kamada Kamada Ltd. the Company is a commercial stage plasma-derived biopharmaceutical company focused on orphan indications, with an existing marketed product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin AAT in a highly-purified, liquid form, as well as other plasma-derived immune globulins. The Companys flagship product is GLASSIA, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited and in other countries through local distributors. The Companys second leading product is KamRab, a rabies immune globulin Human for post-exposure prophylaxis against rabies infection. KamRab is FDA approved and is being marketed in the U.S. under the brand name KEDRAB through a strategic partnership with Kedrion S.p.A. In addition to Glassia and KEDRAB, the Company has a product line of four other plasma-derived pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. The Company has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency. In addition, the Companys intravenous AAT is in development for other indications, such as GvHD and prevention of lung transplant rejection. The Company leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 20 complementary products in Israel that are manufactured by third parties. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Companys lead shareholder, beneficially owning approximately 21 of the outstanding ordinary shares.CONTACTS: Chaime Orlev Chief Financial Officer Yedid LifeSci Advisors, LLC 646-597-6989 